Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus FULVICIN U F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus FULVICIN U F.
FULVICIN P/G 330 vs FULVICIN-U/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
330 mg orally once daily with fatty meal to enhance absorption.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Category C
Category C
Antifungal
Antifungal